Evaluation of potential protective effects of curcumin versus metformin in experimentally-induced metabolic syndrome in rats

Metabolic syndrome [MetSyn] is the clustering of various interrelated risk factors of metabolic origin that increased incidence of cardiovascular diseases and type 2 diabetes. In this study the effectiveness of curcumin was evaluated in comparison with metformin in fructose-induced MetSyn disease in rats. Fructose was fed [10% solution in drinking water] for 8 weeks during which groups of rats were administered once daily vehicle [2% carboxy methyl cellulose], curcumin [40 and 80 mg/kg], metformin [100 and 200 mg/kg], their combinations and compared with group received tap water instead of fructose. The results revealed that induction of MetSyn was associated with glucose intolerance, insulin resistance alongside with increased weights of body and visceral fats. This was accompanied with an elevation of arterial blood pressure. Meanwhile, it caused disturbances in lipid profile [triglyceride, total cholesterol, HDL-C and LDL-C] and both oxidative stress [inalondialdehyde, 8-Iso-PGF[2alpha] and superoxide dismutase] and inflaminatory status [tumor necrosis factor-a, interleukin-6, C- reactive protein and adiponectin] parameters. Each of curcumin and metformin significantly prevents, to variable extents, the progression of most of these signs of MetSyn. Furthermore, the efficacy of each of the two drugs in question was significantly augmented upon their concurrent administration. These protective effects of the two drugs under investigation presumably may be relevant to their ability to reduce the oxidative stress and to ameliorate the inflammatory processes

Evaluation of potential curative effects of curcumin versus metformin in experimentally-induced metabolic syndrome in rats

Metabolic syndrome [MetSyn] is an important public health concern that predisposes individuals to the development of cardiovascular diseases and/or type 2 diabetes [T2D]. In the present study the curative effect of curcumin, the active ingredient of spice turmeric, was assessed in comparison with metformin, the antidiabetic agent, against fructose-fed rats [FFR] model of MetSyn. Seven groups of rats were fed with 10% fructose solution in drinking water for 8 weeks. At the beginning of 9[th] week, the groups of rats received respectively once daily the vehicle [2% carboxy methyl cellulose, CMC], curcumin [40 and 80 mg/kg], metformin [100 and 200 mg/kg] and their combinations for additional 2 weeks. Moreover, another group received plain tap water instead of fructose [normal control group]. The results of this study demonstrated that fructose-feeding was coupled with insulin resistance [IR], impaired glucose tolerance [IGT] together with elevation in body and visceral fat weights. This was associated with elevation of arterial blood pressure [ABP]. Meanwhile, fructose-feeding produced alterations in lipid profile [triglyceride [TG], total cholesterol [TC], High-density lipoprotein-cholesterol [HDL-C] and low-density lipoprotein-cholesterol [LDL-C]] and both oxidative stress [malondialdehyde [MDA], 8-iso-prostaglandin F[2 alpha] [8-iso-PGF[2 alpha]] and superoxide dismutase [SOD]] and inflammatory status [tumor necrosis factor-alpha [TNF-alpha] interleukin- 6 [IL-6], C-reactive protein [CRP] and adiponectin] parameters. Administration of curcumin and metformin significantly ameliorated, to variable extents, the development of most signs of MetSyn. Furthermore, the effectiveness of the two drugs was augmented upon their coadministration. These curative effects of curcumin and metformin may probably be relevant to their antioxidant and anti-inflammatory activities

Comparative study of cardiovascular effects of losartan and captopril in rabbits

Drugs that interfere with renin - angiotensin system [RAS] play a prominent role in treatment of cardiovascular diseases. These drugs include two groups, angiotensin converting enzyme inhibitors e.g. captopril and angiotensin II receptor blockers e.g. losartan. This work was performed to investigate the effects of chronic administration [60 days] of each of losartan and captopril on the progression of atherosclerosis, serum lipids, glutathione peroxidase activity and on arterial blood pressure in rabbits fed with 1% cholesterol enriched diet. Specimens from different levels of aorta, heart, liver and kidneys of each rabbit were formalin-fixed, paraffin-embedded and stained with haematoxylin and eosin and Verhoff's stains. The serum lipids were estimated by enzymatic colorimetric tests. The glutathione peroxidase activity in the aortic tissues was determined by a modified spectrophotometric method. Our results showed that administration of each of losartan and captopril had the ability to attenuate the progression of atherosclerosis in hypercholesterolemic rabbits. The antiatherogenic effect of losartan was more pronounced than that of captopril. Both drugs also prevented the effect of hypercholesterolemia on the heart and liver compared to the non-medicated hypercholesterolemia rabbits. On the other hand, cholesterol-fed rabbits treated with each of losartan and captopril demonstrated significant decrease in total cholesterol, triglycerides and low density lipoprotein with an insignificant increase in high density lipoprotein compared to untreated hypercholesterolemia rabbits. However, the intensity of changes produced by losartan was of greater extent than that produced by captopril. This study revealed an increase in the glutathione peroxidase activity in aortic tissues of groups of atherosclerotic animals treated with either losartan or captopril in comparison with the non-mediated atherosclerotic rabbits. Moreover, a lowering in the blood pressure was recorded in cholesterol-fed rabbits treated with either losartan or captopril. In conclusion, these results are encouraging and the beneficial antiatherosclerotic effects of both drugs are presumably attributed to then ability to interrupt influences on the RAS. In addition, their contributory role of the possible antioxidant properties of these drugs must not be ruled out. Besides, the documented ability of these drugs to accumulate kinins and nitric oxide as well as prevention of the vascular endothelial dysfunction can not be neglected

Serum level monitoring of digoxin in cardiac patients attending Assiut University Hospitals: utility in therapy optimizations.

This study addressed the utility of digoxin level monitoring in the optimization of drug therapy. The results revealed toxic serum levels [> ng/ml] only in 91 of the 147 suspected cases. Among 61 patients with inadequate response, low concentrations [<0.7 ng/ml] were noticed. Similarly, in ten patients with non-compliance, very low subtherapeutic levels were observed even to the nil level in 50% of the cases. Accordingly, therapeutic failure of digoxin resulting from under dosage or non-compliance could be detected by TDM that helped in appropriate intervention and in the achievement of optimum clinical outcome. On the other hand, the TDM in clinically controlled cardiac patients indicated that the target concentration of digoxin required to the control heart failure and/or supraventricular arrhythmias could range from 0.7 ng/ml to 2.0 ng/ml. These data indicated that the international therapeutic range [0.7-2.0 ng/ml] of digoxin could be also applied to Upper Egypt cardiac patients. In addition, this study demonstrated the importance of proper sampling time and measurement of serum potassium and creatinine in the interpretation of digoxin level data